Immunotherapy is a rapidly growing field and represents a paradigm shift in the treatment of malignancies as it offers a new therapeutic approach beyond surgery, conventional chemotherapy, and radiation treatment. Targeting immune checkpoints, such as cytotoxic T-lymphocyte-associated antigen 4 and programmed death 1/programmed death ligand 1 has had immense clinical success resulting in sustained treatment response for a subset of patients with certain malignancies such as melanoma, non-small-cell lung cancer, urothelial carcinoma, squamous cell carcinoma of the head and neck, renal cell cancer, hepatocellular cancer, and metastatic colorectal cancer. Importantly, there has been limited success in the use of immunotherapy in the treatment of pancreatic cancer. Investigation into the complex tumor microenvironment of pancreatic cancer that is composed of immune cells, stromal cells, and extracellular matrix proteins has begun to shed light on important attributes of this microenvironment that act as barriers to the effective use of immunotherapy. In this review, we will discuss the progress that has been made in treating pancreatic cancer with immunotherapy, the barriers that have limited treatment success, and breakthroughs with combination treatments that hold promise for the future.
(anti-PD-1) and anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4). 5, 6 The ineffectiveness of immunotherapy in pancreatic cancer may be explained by these tumors being non-immunogenic. 7 One explanation for the non-immunogenic nature of these tumors is their poor antigenicity. A key initial step of launching effective anti-tumor immunity is tumor antigenicity; T cells must be able to recognize malignant cells as foreign to elicit their destruction. The antigenicity of tumors can be, in part, inferred by their mutational landscape.
Solid tumors such as pancreatic cancer, colon cancer, and breast cancer contain an average of 33 to 66 somatic mutations that result in altered protein production and, in turn, could lead to the expression of "foreign" antigens. Conversely, melanoma and lung cancer have approximately twice as many somatic mutations making them relatively more antigenic. 8 Despite the decreased antigenicity of pancreatic cancer when compared to melanoma and lung cancer, multiple studies have indicated that the human immune system can develop an immune response to pancreatic cancer and generate functional anti-tumor T cells. 9, 10 This suggests that other mechanisms are likely contributing to the non-immunogenic nature of pancreatic cancer.
It is well known that the interaction of the immune system and cancer cells is a dynamic process that can eliminate antigenic cancer cells, but can also evolve to a phase where cancers escape from immune surveillance. 11 The process of immune escape is multifacto- In this review we will briefly describe the limited success that has been seen with immune checkpoint blockade and pancreatic cancer vaccines and explore the unique tumor microenvironment of pancreatic cancer that acts to limit the effectiveness of immunotherapy. Last, we will highlight how the tumor microenvironment can be targeted in combination with immunotherapy to unleash the potential of immunotherapy as an effective treatment modality in pancreatic cancer.
| LIMITED SUCCE SS OF TRADITIONAL

IMMUNOTHE RAPY
| Immune checkpoint blockade
Cytotoxic T-lymphocyte-associated antigen 4 is a coinhibitory receptor expressed on activated CD4 + and CD8 + T cells and competes with CD28 for ligands B7-1 and B7-2. Blockade of CTLA-4 can induce anti-tumor immunity. 12 Ipilimumab is a fully human monoclonal antibody (mAb) that improves overall survival in patients with metastatic melanoma and elicits a long-term survival benefit in a subset of patients. 13 Ipilimumab became the first immune is an anti-PD-L1 monoclonal antibody that can also disrupt the interaction between PD-1 and its ligands, 17 and has been approved for the treatment of non-small-cell lung cancer and urothelial carcinoma. 18 Multiple human studies have indicated that high PD-L1 expression in pancreatic cancer tumors is associated with worse outcomes suggesting that targeting the PD-1/PD-L1 interaction may have therapeutic benefit in these patients. [19] [20] [21] An early preclinical study in a mouse tumor transplant model showed that PD-1 or PD-L1 blockade had an anti-tumor effect which was enhanced when given together with gemcitabine. 19 Unfortunately, these preclinical findings have not translated to clinical success. In a phase I trial of anti-PD-L1 therapy, no patients with pancreatic cancer showed a clinical response. the product of mutated KRAS. 23 All these antigens have the potential to be used as vaccines for pancreatic cancer. In addition, allogenic tumor cell vaccination, using tumor cell lines, can induce effective and tumor-specific immune responses in mouse tumor models. 24 GVAX is a whole-cell vaccine in which pancreatic cancer cells are engineered to express the proinflammatory cytokine granulocyte monocyte-colony stimulating factor (GM-CSF) to further stimulate APC antigen uptake and T-cell priming. 25 A phase I study evaluated the safety and efficacy of GVAX as an adjuvant therapy given in series with chemoradiation therapy in patients with resected pancreatic cancer.
This phase I study showed that vaccination with GVAX was safe. Data from this trial also provided evidence that GVAX was effective in pro- VEGFR2 and a kinesin-family protein (KIF20A). This regimen was well tolerated and, importantly, 58.6% of patients developed a cytotoxic lymphocyte response against KIF20A. In the per-protocol analysis, patients who developed a KIF20A-specific cytotoxic lymphocyte response had a significantly improved disease-free survival. 29 These promising results indicate that vaccine therapy can be a useful immunotherapy in the treatment of pancreatic cancer, but more work is needed to identify key biomarkers that predict response, and to optimize combinatory therapies to increase the effectiveness for all patients.
| Vaccine and immune checkpoint blockade in combination
A phase I study compared ipilimumab and ipilimumab in combination with GVAX in locally advanced and metastatic pancreatic cancer.
This study included 30 patients, randomized 1:1, and showed that combination therapy was safe with evidence favoring increased efficacy with combination therapy. Two patients in the ipilimumab-alone arm showed stable disease at 7 and 22 weeks, whereas three patients in the combination arm had prolonged disease stabilization at 31, 71, and 81 weeks. Patients from both treatment arms who showed prolonged overall survival had higher levels of mesothelinspecific CD8 + T cells in peripheral blood samples after treatment indicating an improved anti-cancer T-cell response. 30 Preclinical studies in melanoma indicated that GM-CSF-producing vaccines in combination with immune checkpoint blockade was able to effectively treat a non-immunogenic melanoma cancer cell line that did not respond to immune checkpoint blockade therapy alone. 31 A similar treatment modality was tested in preclinical models of pancreatic cancer using GVAX in combination with anti-PD-1 therapy. Combination therapy was found to significantly increase median overall survival compared to PD-1 monotherapy with a trend towards has been shown to enhance the efficacy of vaccines in promoting anti-tumor immunity. 57 These findings led to the hypothesis that anti-CD40 agonist mAb therapy could be used in conjunction with chemotherapy as a novel treatment for pancreatic cancer. 58 In preclinical studies, CD40 agonist therapy has elicited tumor regression when used in combination with chemotherapy. [59] [60] [61] In the KPC model of pancreatic adenocarcinoma, combination treatment with gemcitabine and an agonist CD40 antibody resulted in regression of spontaneous tumors in 30% of mice. 59 Agonist CD40 treatment in combination with gemcitabine and nab-paclitaxel also resulted in tumor regression of subcutaneously implanted KPC tumor cells and prolonged overall survival compared to anti-CD40 therapy or chemotherapy alone. 59, 61 In a phase I clinical trial, CD40 agonist mAb therapy in combination with gemcitabine resulted in tumor response in 19% of patients with unresectable chemotherapy na€ ıve pancreatic cancer. 62 Tumor biopsies from these patients showed a dearth of TIL and an abundance of tumor infiltrating macrophages. 62 A second phase I study is aimed at studying the combination of anti-CD40 therapy with nabpaclitaxel and gemcitabine in pancreatic cancer and is currently enrolling (Table 1) 
